NY-AB-INBEV
30.5.2024 07:01:28 CEST | Business Wire | Press release
Today, Danone has joined AB InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD), The Coca-Cola Company, Colgate-Palmolive Company, and Unilever as the fifth partner in the 100+ Accelerator, the groundbreaking program dedicated to pioneering sustainable innovation across global supply chains.
Launched in 2018 by AB InBev, the 100+ Accelerator has rapidly become a cornerstone initiative for catalyzing environmental stewardship and sustainable business practices through global collaboration and groundbreaking solutions in critical areas such as water stewardship, circular economy, sustainable agriculture, and climate action. In 2021, the 100+ Accelerator welcomed its first three partners to expand this unique approach to innovation and to further establish the value proposition of the program’s brand and mission. To date, it has accelerated 148 companies in 38 countries.
“Sustainability is core to our business strategy and fulfills our purpose of dreaming big to create a future with more cheers,” said Ingrid De Ryck, Chief Sustainability Officer of AB InBev. “In the 5 years since its launch, the 100+ Accelerator has helped us identify and scale solutions to business challenges, advance our 2025 sustainability goals and improve resilience across supply chains. We welcome Danone as a strategic partner in the 100+ Accelerator and are excited to continue developing the program’s impact through industry collaboration.”
“Our combined global reach will undoubtedly propel the 100+ Accelerator to new heights, driving broader adoption of sustainable innovations that will benefit our planet, our communities and our future.” Vikram Agarwal, Chief Operations Officer, Danone, also expressed his enthusiasm for the partnership: "This collaboration with 100+ Accelerator is yet another milestone in Danone's sustainability journey and is a direct result of our Partner For Growth program. It shows our commitment to working with all partners across our ecosystem to leverage our respective strengths to create shared value. With 100+ Accelerator, start-ups will be able to harness our internal resources to scale-up innovation that will deliver tangible environmental benefits across the value chain.”
Isabelle Esser, Danone Chief Research, Innovation, Quality and Food Safety Officer added, “We are proud to join the 100+ Accelerator program, which is fully aligned with our ambition to drive sustainable innovation for the future of our planet and our consumers. At Danone, we believe that strong partnerships are essential to help us stay one step ahead of global challenges, while continuing to honor our mission of shaping the food of tomorrow.”
The program's effectiveness is evidenced by its impact:
- Implementation of a range of technologies that help improve water efficiency including nanotechnology, electrochemistry and spectroscopy.
- Enhanced traceability and support systems for smallholder farmers, endeavoring to improve livelihoods and agricultural sustainability across continents.
- Fleet optimization including EV retrofitting, hydrogen co-fueling, aerodynamic solutions and hybrid charging.
- New cooling applications including thermodynamic coatings and magnetic refrigeration.
- Bio-based, compostable packaging alternatives or additives from banana fiber, spent grain, corn husk, bacterial nano-cellulose among others.
Applications for the sixth cohort of the accelerator will open on May 30. Forward-thinking entrepreneurs are invited to apply at www.100accelerator.com.
With the collective capabilities of AB InBev, The Coca-Cola Company, Colgate-Palmolive, Danone, and Unilever, the 100+ Accelerator will continue to scale innovative solutions to create a more sustainable world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529855383/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom